HPV Vaccine May Reduce Cervical Cancer Rates in Developing Countries

Human papillomavirus (HPV) is a set of over 150 viruses; know as papilloma viruses, which encourages a certain type of skin growths. Human papilloma viruses (HPV) are often connected to certain kind of cancer, also known as, carcinogenic HPVs or “high-risk," oncogenic.

Out of 150 types of HPV, 40 types of HPV are contagious, and can be transmitted from person to person during sexual interaction. The transmission of HPV can take place by genitals or oral, even if usually HPV’s is passed on sexually. It is studied that several Human papilloma virus (HPV) appear without any indications and goes away without any treatment.

The major cause of cervical cancer is high-risk HVP infection. More or less all the women have HPV infection, at some point of time, but only few develop into cervical cancer. Immune system, nearly in all the women, is suppresses or reduces HPV. Only a persistent HPV infection leads to the development of cervical cancer.

As per a study, giving human papilloma virus (HPV) vaccine dose for a longer period of time may establish an effectual way to formulate the vaccine to be obtainable to more and more women’s in the underprivileged nations.

According to the researcher, different schedules of dosing vaccine where used to conclude the treatment in the developing country.

The WorldHealth Organization (WHO) has accepted this programmatic limitation that should be considered to be initiated in the national Human papilloma virus (HPV) vaccination programs. Neuzil's team has announced that, delivering Human papilloma virus (HPV) vaccine in flexible timetable, will lets countries to  reduces the cost and increase the availability of vaccination  programs.

Lack of Vitamin D declines the level of estrogen

Vitamin D is important for a good health conditions and can be gained from food such as cereals, milk and by exposing to sunlight. Lack of vitamin D in men is amplified by lowering the levels of estrogen, but not by testosterone.

According to a previous study made deficiency of vitamin D and the low levels of estrogen are at independent threat of hardened and narrow arteries and damaged bones. A national study was carried out by the researchers, for examining the relation involving Vitamin D, bone health, and heart. It is also said that the, vitamin D supplements which can be prescribed to cure osteoporosis, can be useful to avoid heart disease.

Vitamin D, testosterone and estrogen are steroid hormones, formed from cholesterol. The level of cholesterol in blood controls bone health and arterial. Research gives a much improved understanding as to how Vitamin D, estrogen and testosterone work to affect bone health and cardiovascular health.

After using the same measure of estrogen levels, vitamin D deficiency in men were also at high risk of cardiovascular syndrome. This results support the point as to how important it is to have a appropriate quantity of vitamin D are to good for bone health and risk of rising osteoporosis and heart disease is very high on the combined interaction of how any such vitamin shortage interacts with both the sex hormones.

Natrecor a heart failure drug is found to be ineffective

A latest study published by New England Journal of Medicine says, Natrecor (nesiritide),the heart failure medicine is not effectual and is associated to increasing rates of possibly hazardous low blood pressure.

The heart failure drug Natrecor was approved in 2001 to help patients breathe without difficulty. According to the research, since the medicine had no major consequence on breathing problems or any other disease difficulty may also cause low blood pressure.

The study authors have noted that the research has recognized the possible risk and benefits of the drug in people with heart failure who have serious difficulty in breathing a condition also known as dyspnea as the illness is worsening.

To come up with new drugs, we require adequate plan and must have enough data, to rework the whole process so that the doctors and patients are comfortable. Billions of dollars were spent on Natrecor (nesiritide), where as we could have used Lasix which costs penny for single dose. We need to rethink the entire pharmaceutical industry process.

Even though, there were small non-specific effect on reducing death, re-hospitalization and improve dyspnea with nesiritide use for severely worsening heart failure. This result improves clinicians about the possible danger and benefits of Natrecor (nesiritide) in treating such patients.

In 2001 Food and Drug Administration (FDA), U.S. approved nesiritide, the anxiety were raise which may also be associated with worsening of renal functioning and mortality.

It is said that Nesiritide, shall be not be taken away from the market, as it doesn't harm anyone, just because it doesn't hurt people it doesn't means that it should be made available in the market.

Teva Loses Battle to Pfizer, Succeed Patent Challenge

Teva Pharmaceutical Industries gave a tough fight to protect the patent of the best- sold drug in the market. Teva Pharmaceutical Industries has lost the challenge, as they are not permitted to market the generic version of the Viagra.

As Pfizer Pharma has won the legal battle, and can retain the patent rights of the most blockbuster drug, that cures male impotent, called as Viagra. The major drug used for the preparation of Viagra is Slidenafil Citrate. Teva Pharmaceutical Industries will not be allowed to market the generic version of this medicine till October, 2019, by order.

As Pfizer Pharma, continues to carry on with the exclusive right into producing and marketing Viagra. The management of Pfizer Pharma is extremely content about the fact that the court has understood the necessity and the effectiveness of this drug which is used to treat erectile dysfunction (ED) or male impotent. Pfizer Pharma, also says that court has not only protected their intellectual property rights; but has also protected their patent rights from getting violated in the market.

Teva Pharmaceutical Industries builds a victorious generics industry, standing to test the patents exclusively for the owned drugs. Teva is now finding itself to the other side where they have secured its own owned products. Teva Pharmaceutical Industries has declared that even they are satisfied with the court’s result and are waiting to begin an experiment on September 7, 2011’.

Legal Action Over FDA by US Cigarette Companies

Lorillard Tobacco, Santa Fe Natural Tobacco, Commonwealth Brands, Liggett Group and, RJ
Reynolds Tobacco are the five companies that are involved in common lawsuit filed against, US
Food and Drug Administration (FDA).

All these listed major cigarette companies say that, the lawsuit has been filed against Food and Drug Administration (FDA), because the new graphic warning labels will be essential on the cigarette packets only from September 2012 onwards. The suit was filed to holdup the challenges to reinforce the upcoming new law.

In the list of complaint approximately adds 41 pages, which include saying, the newly designed
label would unlawfully force the cigarette manufactures to make their customers miserable, discouraged and terrified before purchasing their product. They are also asking Food and Drug Administration (FDA) to come-up with simple and effective uncontroversial warnings label rather then to make the cigarette pack a public notice for anti-smoking campaign by government.

All the major cigarette companies are arguing over the new law, because it is violating the constitutional right of every citizen of free speech. In the new law government wants the Cigarette companies to endorse their anti-smoking note on the pack. All the major tobacco companies have joint their hands to fight against this graphic label warning, as it is violating their freedom of speech.